Drug Interaction Database (DIDB®)
Drug Interaction Database (DIDB®)
Harness the industry’s largest expertly curated database to assess drug interactions and safety.
DIDB® has the largest scientist curated collection of qualitative and quantitative human in vitro and clinical (in vivo) information related to various extrinsic and intrinsic factors that can affect drug exposure.
These factors include interacting co-medications, excipients, food products, natural products, herbs, tobacco, organ impairment, and genetics.
The unique value of the Certara drug interactions database
Continuous incorporation of new findings
Dedicated in-house experts analyze over 100 publications and several new drug application (NDA) and new biologics license application (BLA) packages each month.
Scientist-curated content
Daily updates curated by a team of research scientists with extensive expertise in drug-drug interactions (DDIs) and pharmacogenetics to maintain a high degree of accuracy.
Enable informed decision-making
Supports scientific decision-making process when evaluating pharmacokinetic (PK)-based drug interactions and drug safety.
Make predictions beyond
observations
All interactions are characterized based on their mechanism(s) and studies are organized accordingly for quick retrieval and identification of a drug DDI profile. This information enables DDI predictions based on the mechanistic characteristics of drugs, even when no clinical evaluations are available.
Analysis beyond DDIs
Information related to various extrinsic and intrinsic factors such as excipients, food products, natural products, herbs, tobacco, organ impairment, and genetics.
User-friendly interface
Allows users to efficiently retrieve up-to-date information from a large body of publications and regulatory documentation.
What can the drug interactions database do?
Retrieve DDI information with over 70 pre-formulated queries
Search the DIDB using multiple query options: drug name, therapeutic class, enzymes, transporters, gene name, in vitro parameters, PK parameters, and more.
Easily filter query results to perform metadata analysis
Common metrics are used across all studies to allow metadata analysis of quantitative results. Results can be viewed, customized, and downloaded in multiple formats, allowing users to compile and organize the large body of information available.
Explore in-depth drug monographs
DIDB monographs summarize the main mechanistic and quantitative findings including the PK profile, DDI summary, and QT summary, as well as information regarding the overall DDI risk level, any post-marketing requirements and commitments, and label recommendations for clinical use.
Support static predictions & PBPK modeling
Use DIDB query results to guide input parameter selection and provide context for results obtained for candidate compounds.
Create custom extracts to support new approaches in personalized medicine
The Drug Interaction Solution team’s experience in data curation and its strong expertise in drug interactions can assist in leveraging the extensive human in vitro and in vivo content of DIDB to best suit project-specific needs. The mechanistic and quantitative features and breadth of content in DIDB can support the emergence of new approaches in personalized medicine, which aim to select the most appropriate drug and dosage for each patient.
Drug Interaction Solutions Consulting Services
Get more out of DIDB with Expert Consulting Services
Using Certara’s Drug Interaction Database (DIDB), Drug Interaction Solutions (DIS) consultants provide services related to the systemic evaluation of the literature and NDA reviews to assess the risk of pharmacokinetic (PK) drug-drug, food-drug, gene-drug and disease-drug interactions.
What people say about us
Request a free trial of DIDB®
Complete the form to book your no-obligation trial of the Drug Interaction Database … and see how better off you could be!
Meet our Drug Interaction Solutions Experts
Isabelle Ragueneau-Majlessi, MD, MS
Senior Director
Dr. Ragueneau is a Clinical Professor Emeritus from the University of Washington where she co-founded the Drug Interaction Database (DIDB) over 25 years ago. At Certara, she is the head of the Drug Interaction Solutions program and leads the Center of Excellence in Drug Interaction Science. She is a clinical pharmacologist by training, with a deep expertise in the evaluation of drug-drug interactions mechanisms and clinical significance. In 2022, she received the Gary Neil prize for innovation in drug development from the ASCPT in recognition of her extensive work with the DIDB and the impact of the tool on drug interaction research.
Jingjing Yu, MD, PhD
Director
Dr. Yu joined Certara in 2023 following the acquisition of the University of Washington Drug Interaction Solutions program. With over 15 years of experience in drug metabolism and clinical pharmacology, she brings a unique expertise in the field of drug interactions, gained through her work in both academia and industry. At Certara, Dr. Yu is Director at the Drug Interaction Solutions and a core member of Center of Excellence in Drug Interaction Science. She is also an Affiliate Associate Professor of the Department of Pharmaceutics at the University of Washington in Seattle, WA.
